MKC-1

N/A

Report date: 2026/05/20 20:02:01
NME

Base Information

Drug NameMKC-1
Drug Alias NameR-440MKC-1Ro-31-7453
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionmTOR Complex 2 inhibitorsMammalian target of Rapamycin (mTORC1) inhibitors
TargetsMammalian target of Rapamycin (mTORC1)mTOR Complex 2
Therapy Area/IndicationsSolid tumoursPrimary MyelofibrosisMyelodysplastic Syndromes +[11] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited States
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesF. Hoffmann-La Roche Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNational Cancer InstituteCasi Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsSolid tumoursPrimary MyelofibrosisMyelodysplastic Syndromes +[11] 

Other Information

ATC CodeN/A
Related LinksN/A